CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
CytoMed Therapeutics (NASDAQ:GDTC) announced the publication of a preclinical study conducted in collaboration with MD Anderson Cancer Center, focusing on donor-derived γδ T cells for treating acute myeloid leukemia (AML). The research demonstrates promising potential for CytoMed's allogeneic γδ T cell therapy (CTM-GDT).
The study supports the company's advancement of γδ T cell-based treatments, following their leading product CAR-γδ T cells (CTM-N2D) which is currently in Phase 1 clinical trials in Singapore. CytoMed plans to expand clinical trials across Southeast Asia to provide novel immunotherapy options for patients with limited treatment alternatives.
CytoMed Therapeutics (NASDAQ:GDTC) ha annunciato la pubblicazione di uno studio preclinico condotto in collaborazione con MD Anderson Cancer Center, focalizzato sulle cellule T γδ derivate da donatore per trattare la leucemia mieloide acuta (AML). La ricerca mostra un potenziale promettente per la terapia a base di cellule T γδ allogeniche di CytoMed (CTM-GDT). Lo studio sostiene l'avanzamento dei trattamenti basati su cellule T γδ dell'azienda, a seguito del loro prodotto di punta CAR-γδ T cells (CTM-N2D), attualmente in studi clinici di fase 1 a Singapore. CytoMed intende espandere i trial clinici in Asia sudorientale per offrire nuove opzioni di immunoterapia ai pazienti con opzioni di trattamento limitate.
CytoMed Therapeutics (NASDAQ:GDTC) anunció la publicación de un estudio preclínico realizado en colaboración con MD Anderson Cancer Center, centrado en células T γδ derivadas de donantes para el tratamiento de la leucemia mieloide aguda (AML). La investigación demuestra un potencial prometedor para la terapia de células γδ T alogénicas de CytoMed (CTM-GDT). El estudio respalda el avance de los tratamientos basados en células γδ T de la empresa, tras su producto líder CAR-γδ T cells (CTM-N2D), que actualmente se encuentra en ensayos clínicos de Fase 1 en Singapur. CytoMed planea ampliar los ensayos clínicos en el sudeste asiático para ofrecer nuevas opciones de inmunoterapia a pacientes con opciones de tratamiento limitadas.
CytoMed Therapeutics (NASDAQ:GDTC)는 MD Anderson Cancer Center와의 협력으로 수행된 전임상 연구의 발표를 발표했습니다. 이 연구는 기증자 유래 γδ T세포를 이용한 급성 골수성 백혈병(AML) 치료에 초점을 맞추고 있습니다. 연구는 CytoMed의 동종 γδ T세포 치료제(CTM-GDT)에 대한 유망한 가능성을 보여줍니다. 이 연구는 현재 싱가포르에서 1상 임상시험 중인 대표 제품 CAR-γδ T 세포 (CTM-N2D) 이후 γδ T 세포 기반 치료의 발전을 뒷받침합니다. CytoMed는 말레이시아를 포함한 동남아시아 전역으로 임상시험을 확장해 치료 옵션이 제한된 환자들에게 새로운 면역치료 옵션을 제공할 계획입니다.
CytoMed Therapeutics (NASDAQ:GDTC) a annoncé la publication d'une étude préclinique réalisée en collaboration avec le MD Anderson Cancer Center, axée sur les cellules T γδ dérivées du donneur pour le traitement de la leucémie myéloïde aiguë (LMA). Les résultats démontrent un potentiel prometteur pour la thérapie à base de cellules T γδ allogéniques de CytoMed (CTM-GDT). L'étude soutient l'avancement des traitements basés sur les cellules T γδ de l'entreprise, à la suite de leur produit phare CAR-γδ T cells (CTM-N2D) actuellement en essais cliniques de Phase 1 à Singapour. CytoMed prévoit d'étendre les essais cliniques à travers l'Asie du Sud-Est pour offrir de nouvelles options d'immunothérapie aux patients ayant des options de traitement limitées.
CytoMed Therapeutics (NASDAQ:GDTC) gab die Veröffentlichung einer präklinischen Studie bekannt, die in Zusammenarbeit mit dem MD Anderson Cancer Center durchgeführt wurde und sich auf spendereigene γδ-T-Zellen zur Behandlung von akuter myeloischer Leukämie (AML) konzentriert. Die Forschung zeigt vielversprechendes Potenzial für CytoMed's allogene γδ-T-Zell-Therapie (CTM-GDT). Die Studie unterstützt das Vorankommen der γδ-T-Zell-basierten Behandlungen des Unternehmens, nach ihrem führenden Produkt CAR-γδ T cells (CTM-N2D), das sich derzeit in Phase-1-Studien in Singapur befindet. CytoMed plant, klinische Studien in ganz Südostasien auszuweiten, um Patienten mit begrenzten Behandlungsalternativen neue Immuntherapieoptionen zu bieten.
أعلنت CytoMed Therapeutics (المدرجة في ناسداك: GDTC) عن نشر دراسة قبل سريرية تمت بالتعاون مع MD Anderson Cancer Center، وتركز على خلايا γδ T المانحة لعلاج سرطان الدم النقوي الحاد (AML). تُظهر الدراسة إمكانات واعدة لعلاج γδ T الخلوي-allogénico من CytoMed (CTM-GDT). تدعم الدراسة تقدم العلاجات المعتمدة على خلايا γδ T للشركة، عقب منتجها الرائد CAR-γδ T cells (CTM-N2D) الذي يمر حالياً بتجارب سريرية من المرحلة الأولى في سنغافورة. تخطط CytoMed لتوسيع التجارب السريرية عبر جنوب شرق آسيا لتوفير خيارات علاج مناعي جديدة للمرضى الذين يواجهون خيارات علاج محدودة.
CytoMed Therapeutics（纳斯达克股票代码：GDTC）宣布与MD Anderson癌症中心合作开展的一项前临床研究发表，研究聚焦于供体来源的γδ T细胞用于治疗急性髓系白血病（AML）。该研究显示了 CytoMed 的同种 γδ T 细胞治疗（CTM-GDT）的潜力。研究支持公司在γδ T 细胞治疗领域的推进，继其旗舰产品 CAR-γδ T 细胞（CTM-N2D）目前在新加坡进行的1期临床试验之后。CytoMed 计划在东南亚扩大临床试验，为治疗选择有限的患者提供新的免疫治疗选项。
- Successful collaboration with prestigious MD Anderson Cancer Center validates research
- Promising preclinical results for CTM-GDT therapy in treating AML
- Company already has another product (CTM-N2D) in Phase 1 clinical trials
- Plans for expansion of clinical trials across Southeast Asia
- Research is still in preclinical stage, requiring further clinical validation
- No immediate revenue potential as treatments are not yet commercialized
Insights
CytoMed's preclinical study shows promising results for donor-derived γδ T cell therapy against acute myeloid leukemia, advancing their immunotherapy pipeline.
The collaborative research between CytoMed Therapeutics and MD Anderson Cancer Center represents a significant advancement in the field of allogeneic immunotherapy for acute myeloid leukemia (AML). The study focuses on donor-derived Vγ9Vδ2 T cells as a potential "off-the-shelf" treatment approach, which is particularly noteworthy because AML remains a challenging hematologic malignancy with limited treatment options and poor outcomes for many patients.
The preclinical findings provide scientific validation for CytoMed's γδ T cell platform technology. What makes this approach particularly promising is that γδ T cells can recognize and target cancer cells without requiring the matching of human leukocyte antigens (HLA), potentially enabling broader patient application compared to other cell therapies. The allogeneic (donor-derived) nature of this therapy is also significant as it could allow for scaled manufacturing and immediate availability, addressing major limitations of autologous cell therapies.
This research complements CytoMed's ongoing clinical development pipeline, notably their lead product CTM-N2D (CAR-γδ T cells) currently in Phase 1 trials. The company appears to be building a diversified portfolio of γδ T cell-based therapies with applications across both hematological malignancies and potentially solid tumors. The announcement signals CytoMed's intention to advance this second candidate toward clinical trials specifically in Southeast Asian populations, suggesting a strategic regional focus for their development efforts.
SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the promising potential of CytoMed’s allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach.
“These findings provide the rationale for further clinical study of allogeneic donor-derived γδ T cells in treating AML as well as other cancers. It will facilitate our endeavour to advance our next γδ T cell-based product into clinical trial after our leading product CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore.” said Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and co-author of the paper.
Mr. Peter Choo, Chairman of CytoMed commented, “This research provides more evidence for applying allogeneic γδ T cells to hematologic malignancies and we are planning to move into clinical trials in Southeast Asia and bring novel immunotherapy options to patients with limited treatment alternatives.”
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention: Evelyn Tan, Chief Corporate Officer
FAQ
What are the key findings of CytoMed's (GDTC) research collaboration with MD Anderson Cancer Center?
What is the current development stage of CytoMed's (GDTC) cell therapy products?
What are CytoMed's (GDTC) expansion plans for clinical trials?
Who collaborated with CytoMed (GDTC) on the AML research study?
